Evidence map›Paper›PMID 31756003›Full record

Trial reportTransfusion2020

Evaluation of post-thaw CFU-GM: clinical utility and role in quality assessment of umbilical cord blood in patients receiving single unit transplant.

Eiman Hussein, Todd DeFor, John E Wagner, Darin Sumstad, Claudio G Brunstein, David H McKenna

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Transfusion, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Eiman HusseinDepartment of Laboratory medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-1342-1560
Todd DeForMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
John E WagnerBlood and Marrow Transplant Program, Department of Pediatrics, Minneapolis, Minnesota.
Darin SumstadDepartment of Laboratory medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
Claudio G BrunsteinBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
David H McKennaDepartment of Laboratory medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
University of Minnesota · USNational Marrow Donor Program · USUniversity of Minnesota Medical Center · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Integrated training in development and clinical practice of cell-based therapiesR25HL128372 · NHLBI · UNIVERSITY OF MINNESOTA · PI HUBEL, ALLISON, MCKENNA, DAVID HURLEY · 2015 to 2019
$553k
NCATS NIH HHS UL1 TR002494NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA077598NHLBI NIH HHS R25 HL128372
6 · The paper itself

Abstract

backgroundThe CFU assay is considered the only in vitro assay that assesses the biologic function of hematopoietic stem and progenitor cells (HSPC). STUDY DESIGN AND

methodsTo investigate the impact of post-thaw CFU-GM counts on the quality of umbilical cord blood (UCB), we studied transplant outcomes in 269 patients receiving single UCB transplant. We also correlated the post-thaw CFU-GM counts of 1912 units with the pre-freeze and post-thaw graft characteristics, hoping to optimize selection criteria of UCB. Data analysis included: total nucleated cells, viability, CD34+, nucleated red blood cells (NRBC), hematocrit, frozen storage time, and cord blood bank (CBB).

resultsWe demonstrated an association between post-thaw CFU-GM dose and the speed of neutrophil and platelet engraftment (p < 0.01). Higher post-thaw CFU-GM dose showed an increased benefit for neutrophil and platelet engraftment (p < 0.01). Post-thaw CD34+ cell dose and CFU-GM dose were strongly correlated (r = 0.78). However, CFU-GM dose showed additional benefit for patients receiving the lowest quartile of CD34+ dose. HLA disparity did not adversely impact either neutrophil or platelet engraftment. Post-thaw CFU-GM/million nucleated cells plated showed moderate correlation with pre-freeze and post-thaw CD34+ and weak correlation with other parameters. Post-thaw CFU-GM was not influenced by storage time, but was impacted by the CBB from which the unit is obtained (p < 0.01).

conclusionPost-thaw CFU-GM is an effective measure of the quality and efficacy of the UCB graft, particularly adding valuable clinical information when the CD34+ cell dose is low. Consideration of pre-freeze CD34+ cell content and CBB as additional selection criteria is warranted.

Indexed as

Cord Blood Stem Cell TransplantationCryopreservationHematologic NeoplasmsAdolescentAdultAgedBlood PlateletsChildChild, PreschoolFemaleGraft SurvivalGranulocyte-Macrophage Progenitor CellsHumansInfantMaleMiddle Aged

Identifiers

PMID31756003
PMCPMC7318782
OpenAlexW2991169144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.